We are excited to present our latest oncology data at one of Europe’s premier oncology conferences, the European Society for Medical Oncology (ESMO) 2016 Congress, live in Copenhagen this week.
Our established heritage in the development and commercialisation of novel oncology medicines is reflected in the depth and breadth of our industry-leading pipeline, and as evidenced by 46 presentations across tumour types and molecules at the ESMO 2016 Congress, we remain committed to following the science with the aim of transforming the cancer treatment paradigm.
Latest from ESMO 2016 Congress
PatientView Survey on use of scientific information
This year we commissioned a survey to better understand how the patient and caregiver community view the landscape of science communications. Reaching 124 patient and caregiver group representatives, we uncovered the increasing need for accessible scientific information for individuals with cancer and their families.
Hormone therapy for metastatic breast cancer: understanding resistance, improving outcomes
John Boyer, Global Medical Affairs Leader, Breast Cancer, AstraZeneca
There are many forms of hormone therapy available for patients with metastatic breast cancer but sometimes tumours can become resistant making some or all of these therapies less effective. Understanding these tumours and their resistance tendencies can influence treatment options and outcomes.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Projects in our pipeline
New molecular entity approval in the last quarter
New molecular entities in our late-stage pipeline
AstraZeneca’s work environment is dynamic and fosters innovation. We believe where there’s energy, there’s fulfillment, and with jobs from Cambridge, UK to Shanghai, China, we’ve got the role for you.
Page Atlas ID: 1013706.011
Date of next review: October 2017